百极优棠

Baiji Youtang is a clinical-stage biotechnology company focused on developing next-generation treatments for metabolic diseases, particularly obesity and type 2 diabetes. The company leverages a proprietary peptide engineering platform to create multi-target agonists, including its lead candidate BJT-7011, a GLP-1/GIP/GCGR triple receptor agonist. These therapies are designed to offer enhanced efficacy in weight reduction and metabolic regulation compared to existing mono- or dual-agonists. Headquartered in Beijing, the company was founded by industry veterans with a track record in biologics development and is strategically backed by Bio-Thera Solutions. The company is currently advancing its pipeline through early-stage clinical trials in China.